Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Zoetis Inc    ZTS

News SummaryMost relevantAll newsSector newsTweets 

Zoetis Inc : APOQUEL® (oclacitinib tablet) Now Available to Treat ‘Itchy’ Dogs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/20/2014 | 06:25pm CET

FLORHAM PARK, N.J. - Jan. 20, 2014 - Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition where APOQUEL would be indicated.

"When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. After gaining five years of experience with APOQUEL through my involvement in clinical trials, I've learned firsthand the difference this treatment can make to a dog and its owners in stopping the itch, but without many of the side effects that are common with steroids," said Thomas Lewis II, DVM, DACVD, practicing veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz. He noted this has been the case even for those dogs that failed to respond to conventional therapies.

"Pet owners who complained that their dogs would wake them up in the middle of the night due to intense itch have told me that after treatment with APOQUEL, the household can sleep more peacefully," Dr. Lewis said. "In my 28 years of practice, this is the most exciting new treatment for the management of itch associated with allergic and atopic dermatitis in dogs, which can often be a challenging and complex condition to treat."

APOQUEL was approved by the U.S. Food and Drug Administration in May 2013 and is the first and only Janus kinase (JAK) inhibitor approved for veterinary use. Its novel mode of action specifically targets and inhibits the cytokines involved in itch and inflammation with minimal activity against cytokines involved in hematopoiesis or innate immune function. Clinical studies have shown that APOQUEL provides rapid relief from itching and improves inflammation in dogs that suffer from allergies, without many of the side effects commonly associated with steroids. In a trial of dogs with allergic dermatitis, APOQUEL produced rapid onset of efficacy within 24 hours. In a trial of dogs with atopic dermatitis, dogs treated with APOQUEL experienced a significant and long-term reduction in itch and inflammation at day 28 of the study. In cases where APOQUEL treatment was continued, success rates remained constant through day 112.

"Zoetis is committed to providing treatments for conditions that affect the lives of pets and their owners who care for them," said Mike McFarland, DVM, DABVP, Group Director, Companion Animal Veterinary Operations at Zoetis. "APOQUEL is just one example that shows how we are continuing to invest in innovative new approaches that help veterinarians address real-world conditions, such as allergic and atopic dermatitis."

For more information, please visit www.apoquel.com.

Important Safety Information

APOQUEL® should not be used in dogs less than 12 months of age or in dogs with serious infections. APOQUEL may increase the susceptibility to infection and demodicosis and may exacerbate neoplastic conditions. APOQUEL has not been evaluated in combination with systemic immunosuppressive agents such as glucocorticoids or cyclosporine. APOQUEL should not be used in breeding dogs, or pregnant or lactating dogs. The most common side effects seen in dogs administered APOQUEL were vomiting and diarrhea. APOQUEL has been safely used in conjunction with other common medications including antibiotics and parasiticides and with vaccinations. For Full Prescribing Information visit www.apoquel.com/Apoquel_PI.

About Zoetis

Zoetis (z

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ZOETIS INC
01/11 ZOETIS : Colleagues Make a Difference in Their Communities
01/03 ZOETIS : PHARMAQ Acquires Fish Vaccination Company Nordland Sett Vaks
2016 ZOETIS : FDA Issues Rule for Withdrawal of Approval of New Animal Drug Applicati..
2016 ZOETIS : to Host Webcast and Conference Call on Fourth Quarter and Full Year 201..
2016 ZOETIS : Receives USDA License for CYTOPOINT™
2016 ZOETIS : joins GlobalVetLINK’s VFD system
2016 ZOETIS INC. (NASDAQ : ZTS) Files An 8-K Entry into a Material Definitive Agreeme..
2016 ZOETIS INC. (NYSE : ZTS) Files An 8-K Entry into a Material Definitive Agreement
2016 ZOETIS INC. : Entry into a Material Definitive Agreement, Financial Statements a..
2016 ZOETIS : Receives USDA License for CYTOPOINT™
More news
Sector news : Veterinary Drugs
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Veterinary Drugs
News from SeekingAlpha
01/18 Vet med industry now dominated by four firms; further mergers unlikely
01/18 Zoetis goes ex-dividend today
01/12 Stocks Going Ex-Dividend The Third Week Of January
01/12 Zoetis (ZTS) Presents At 35th Annual J.P. Morgan Healthcare Conference "
01/09 Mars deal throws a spotlight on the pet care sector
Financials ($)
Sales 2016 4 886 M
EBIT 2016 1 565 M
Net income 2016 899 M
Debt 2016 2 719 M
Yield 2016 0,72%
P/E ratio 2016 30,72
P/E ratio 2017 24,90
EV / Sales 2016 6,01x
EV / Sales 2017 5,44x
Capitalization 26 652 M
More Financials
Duration : Period :
Zoetis Inc Technical Analysis Chart | ZTS | US98978V1035 | 4-Traders
Full-screen chart
Technical analysis trends ZOETIS INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 57,5 $
Spread / Average Target 6,6%
Consensus details
EPS Revisions
More Estimates Revisions
Juan Ramón Alaix President, Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Kristin C. Peck Executive Vice President & President-US Operations
Glenn David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS INC0.82%26 652
VIRBAC0.90%1 495
More Results